SONNET BIOTHERAPEUTICS HOLDI (SONN) Forecast, Price Target & Analyst Ratings
NASDAQ:SONN • US83548R4020
1.26 USD
-1.84 (-59.35%)
At close: Dec 2, 2025
1 USD
-0.26 (-20.63%)
After Hours: 12/2/2025, 8:07:49 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SONNET BIOTHERAPEUTICS HOLDI (SONN).
Forecast Snapshot
Consensus Price Target
$20.40
+ 1,519.05% Upside
Next Earnings Forecast
Release DateDec 15, 2025
PeriodQ4 / 2025
EPS Estimate-$0.50
Revenue Estimate
ChartMill Buy Consensus
82.86%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$20.40
Upside
+ 1,519.05%
From current price of $1.26 to mean target of $20.40, Based on 7 analyst forecasts
Low
$20.20
Median
$20.40
High
$21.00
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
7 analysts have analysed SONN and the average price target is 20.4 USD. This implies a price increase of 1519.05% is expected in the next year compared to the current price of 1.26.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
SONN was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about SONN.
In the previous month the buy percentage consensus was at a similar level.
SONN was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-04-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-28 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-12-20 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-08-23 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-05-28 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-05-16 | EF Hutton | Maintains | Buy -> Buy |
| 2024-02-15 | Chardan Capital | Maintains | Buy -> Buy |
| 2023-11-27 | Ladenburg Thalmann | Initiate | Buy |
| 2023-08-16 | Chardan Capital | Maintains | Buy -> Buy |
| 2023-06-26 | EF Hutton | Reiterate | Buy -> Buy |
| 2023-05-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2023-04-19 | EF Hutton | Reiterate | Buy |
| 2023-04-19 | Chardan Capital | Maintains | Buy |
| 2023-02-15 | EF Hutton | Reiterate | Buy |
| 2022-12-19 | EF Hutton | Initiate | Buy |
| 2022-09-22 | Chardan Capital | Maintains | Buy |
| 2022-08-16 | Chardan Capital | Maintains | Buy |
| 2022-02-09 | BTIG | Maintains | Buy |
| 2021-12-20 | Chardan Capital | Maintains | Buy |
| 2021-12-16 | HC Wainwright & Co. | Initiate | Buy |
| 2021-09-15 | BTIG | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateDec 15, 2025
PeriodQ4 / 2025
EPS Estimate-$0.50
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q86.95%
Number of Analysts3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
SONN is expected to report earnings on 12/15/2025. The consensus EPS estimate for the next earnings is -0.5 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 350K -27.08% | 147.8K -57.77% | 18.6K -87.42% | 1.02M 5,383.87% | -100.00% | 10.2M | 32.844M 222.00% | 64.056M 95.03% | 98.94M 54.46% | ||
| EBITDA YoY % growth | -29.66M -18.26% | -18.78M 36.68% | -11.837M 36.97% | -46.206M -290.36% | -53.04M -14.79% | -61.2M -15.38% | -59.67M 2.50% | -46.92M 21.37% | -25.602M 45.43% | N/A | |
| EBIT YoY % growth | -29.67M -18.25% | -18.793M 36.66% | -11.85M 36.95% | 14.802M 224.92% | -54.876M -470.73% | -37.74M 31.23% | -35.598M 5.68% | -34.068M 4.30% | -19.89M 41.62% | 7.14M 135.90% | |
| Operating Margin | -8,477.14% | -12,714.88% | -63,706.99% | 1,451.18% | N/A | N/A | -349.00% | -103.73% | -31.05% | 7.22% | |
| EPS YoY % growth | -1,205.60 53.88% | -240.24 80.07% | -11.35 95.28% | -3.53 68.91% | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | |
|---|---|
| EPS Q2Q % growth | -0.50 86.95% |
| Revenue Q2Q % growth | |
| EBITDA Q2Q % growth | N/A |
| EBIT Q2Q % growth | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-90.14%
EBIT Next 5 Year
-41.82%
SONNET BIOTHERAPEUTICS HOLDI / SONN Forecast FAQ
What do analysts expect the price target to be for SONNET BIOTHERAPEUTICS HOLDI (SONN)?
7 analysts have analysed SONN and the average price target is 20.4 USD. This implies a price increase of 1519.05% is expected in the next year compared to the current price of 1.26.
When does SONNET BIOTHERAPEUTICS HOLDI (SONN) report earnings?
SONNET BIOTHERAPEUTICS HOLDI (SONN) will report earnings on 2025-12-15, after the market close.
What are the consensus estimates for SONN stock next earnings?
The consensus EPS estimate for the next earnings of SONNET BIOTHERAPEUTICS HOLDI (SONN) is -0.5 USD and the consensus revenue estimate is 0 USD.